Genexine receives FTD for DNA vaccine to treat advanced cervical cancer

A Phase II trial evaluated the efficacy and safety of the combination therapy in 65 subjects with HPV 16- and/or HPV 18- positive recurrent or metastatic advanced cervical cancer. Credit: Haymanj / commons.wikimedia.org.